Nalidixic acid, enoxacin, and other antibacterial 4-quinolones inhibit DNA gyrase activity by interrupting DNA breakage and reunion by A subunits of the A2B2 gyrase complex. Despite their clinical importance, the mode of quinolone action and mechanisms of resistance are poorly understood at the molecular level. Using a DNA fragment enrichment procedure, we isolated the gyrA gene from a uropathogenic Escherichia coli strain that encodes a gyrase A protein cross-resistant to a variety of quinolones. When complemented with gyrase B subunit, the purified A protein reconstituted DNA supercoiling activity 100-fold more resistant to inhibition by enoxacin than the susceptible enzyme and failed to mediate quinolone-dependent DNA cleavage. Nucleotide sequence analysis revealed that the gene differed at 58 nucleotide positions compared with the K-12 gyrA sequence. The 875-amino-acid residue-resistant gyrase A protein differed at three positions from its wild-type E. coli K-12 counterpart: tryptophan, glutamate, and serine replaced serine, aspartate, and alanine residues at positions 83, 678, and 828, respectively. By genetic analysis of chimeric gyrA genes in a gyrA(Ts) background, we showed that the Ser-83-*Trp mutation in the gyrase A protein was solely responsible for high-level bacterial resistance to nalidixic acid and fluoroquinolones.
Bacterial DNA is maintained in a negatively supercoiled state by DNA gyrase, an ATP-dependent type II DNA topoisomerase (10) . Gyrase is essential for cell viability, being implicated in a range of DNA transactions, including DNA replication and recombination, and in the control of gene expression (8, 35) . Gyrase catalyzes DNA supercoiling by an interesting and unusual mechanism. It passes a duplex DNA segment through a transient double-stranded DNA break made within a 120-to 150-base-pair (bp) loop of DNA wrapped on the surface of the tetrameric A2B2 gyrase complex. DNA strand passage is the salient mechanistic feature that allows DNA supercoiling and ATP-independent DNA relaxation by gyrase and also accounts for its catenation or decatenation and DNA unknotting activities (3, 16, 18) .
Antibacterial quinolones such as oxolinic acid inhibit DNA supercoiling by gyrase in vitro and rapidly arrest DNA replication in vivo (2, 9, 12, 28) . Addition of detergent to gyrase-DNA complexes formed in the presence of oxolinic acid results in site-specific double-stranded DNA breakage and covalent attachment of the gyrase A subunits to each 5'-phosphate end via tyrosine (Tyr)-122 (6, 7, 9, 15, 22, 31) . Thus, the A subunits appear to promote DNA breakage and reunion during catalysis, a process interrupted by quinolone inhibitors. In contrast, the B subunits bind ATP and are the locus of action of coumarin antibiotics such as novobiocin (11, 20, 30) . The A and B subunits can be individually purified but must be combined to generate the topoisomerase activities of gyrase (14, 19) .
The molecular basis underlying the enzymatic and potent antibacterial effects of quinolones is not yet understood. Given the current clinical and mechanistic interest in quinolones (36) , we have sought to elucidate their mode of action by characterizing quinolone resistance in clinical isolates of Escherichia coli. Here we report the genetic and enzymatic * Corresponding author. characterization of the gyrA gene and its quinolone-resistant gyrase A product from a resistant uropathogenic E. coli strain.
MATERIALS AND METHODS
Materials. E. coli strains used in this study were the following: RW1053 recA A(bio att gal), MK47 and N4186 (19) , DH5 recA gyrA96 (Nalr) ( (29) . Gyrase A and B proteins were purified to near homogeneity from overproducing strains N4186 and MK47 (19) . High-molecular-weight chromosomal DNA from E. coli cultures was isolated as described previously (25) . Plasmid pRM386 carrying the wild-type K-12 gyrA gene was kindly given by Rolf Menzel, E. I. du Pont Experimental Station, Wilmington, Del. Plasmid pBR322 was prepared as described previously (18) . Plasmid pSPT19 was from Boehringer.
Drug susceptibility of E. coli strains. MICs of various antibiotics were determined by the standard broth dilution method, using microdilution plates and an inoculum of 2 x 104 cells per well. Turbidity was scored either visually or by using a Titertek Multiskan microdilution plate reader.
Southern blotting. Genomic restriction maps for the gyrA gene in E. coli 227 or RW1053 were determined as follows.
Chromosomal DNA was digested with either Sacl or HindIll and one of several other restriction enzymes. DNA fragments were separated on 0.8% agarose gels, transferred to nitrocellulose or Hybond-N, and probed with a nick-translated or randomly primed 600-bp Sacl-HindlIl or a 2.8-kb
HindIII fragment from within the wild-type gyrA gene. This indirect end-labeling approach (37) allowed sites to be located relative to the Sacd and HindIII sites internal to the gyrA gene.
DNA cloning of the strain 227 gyrA gene. Genomic DNA was digested with BamHI and KpnI, and the DNA fragments were separated on a 0.8% low-gelling agarose gel. DNA size markers were run in outside lanes, and these sections of the gel were excised, stained with ethidium bromide, and photographed. The unstained gel was cut into slices, and then DNA in the 7-to 8-kb range was purified from the gel by phenol extraction and ethanol precipitation. The DNA was ligated into BamHI-KpnI-cut plasmid pSPT19 and used to transform highly competent E. coli DH5 cells, which were then plated on L-ampicillin plates (25 ,ug/ml) overlaid with Hybond-N filters and incubated at 37°C overnight. Colonies were replica plated, and replica Hybond-N filters were incubated overnight on L-chloramphenicol plates (10 ,ug/ml) to amplify plasmid copy number. Cells were lysed and the DNA was fixed on the filters by UV irradiation. Duplicate filters were hybridized at high stringency to a 600-bp SacIHindIII fragment from the 5' end of the K-12 gyrA gene ( Fig.  1 ) excised from plasmid pRM386 and labeled with [a-32P] dCTP by random priming. Strongly hybridizing colonies were picked from the master plate and grown on a large scale, and their plasmids were isolated and restriction mapped. Two independent positive clones were obtained which contained identical plasmids with 7.5-kb inserts. Both plasmids had functional gyrA genes as demonstrated by their ability to confer temperature-independent growth on strain KNK453, which harbors a gyrA(Ts) allele.
DNA sequence analysis. The 5'-end-labeling, using T4 polynucleotide kinase, was carried out as described previously (6 (29) . Cells were grown in 10 liters of L broth to an optical density at 600 nm of -1.5, pelleted, washed with 50 mM Tris hydrochloride, pH 8.0-10% glycerol-1 mM dithiothreitol, and stored at -70°C as described previously (19) . Bacteria were thawed and treated with lysozyme, and the gyrase A protein was purified by Polymin P and ammonium sulfate precipitation. Protein from VOL. 33, 1989 Quinolone-susceptible gyrA alleles are usually dominant over resistant alleles (13) , and thus it was not feasible to clone the 227 gyrA gene by simple drug selection. We therefore chose a colony hybridization method, using wildtype gyrA probes.
First, a genomic restriction map for the gyrA locus in strain 227 was determined by Southern blotting (Fig. la) . Genomic 227 DNA was digested with both Sacl and HindIll restriction enzymes and probed with a radiolabeled 600-bp Sacl-HindIll fragment from within the K-12 gyrA gene (shown in Fig. 1 (Fig. lb) . To isolate the 227 gene, chromosomal DNA was digested with BamHI and KpnI and DNA fragments in the 7-to 8-kb size range were purified by preparative gel electrophoresis. The DNA, now enriched for the gyrA gene, was ligated into BamHI-KpnI-digested pSPT19, a 3.1-kb plasmid specifying ampicillin resistance and carrying multiple cloning sites. The DNA was used to transform E. coli DH5 (recA). Two independent size-selected libraries were obtained, each consisting of about 240 colonies. These libraries were probed by colony hybridization, using a randomly primed 32P-labeled SacI-HindIII probe from the 5' end of the E. coli gyrA gene (Fig. 1) . Two independent positive clones were obtained ( Fig. 2) which contained identical plasmids with 7.5-kb inserts. Both plasmids had functional gyrA genes as demonstrated by their ability to confer temperature-independent growth on strain KNK453, which harbors a gyrA(Ts) allele.
The frequency of gyrA clones in the two libraries was consistent with the calculated frequency of one positive clone per 160 colonies, using 7-to 8-kb size-selected DNA (23) .
Nucleotide sequence of the resistant gyrA gene. The sequence of the gyrA gene in one plasmid, pMEC5, was determined by the Maxam-Gilbert chemical sequencing method, using a combination of 5'-and 3'-end-labeled DNA fragments ( Fig. 3a and b) (Asp) at position 678, and serine for alanine (Ala) at position 828, arising from C-to-G, C-to-A, and G-to-T transversions, respectively. Figure 4 compares E. coli and Bacillus subtilis gyrase A protein sequences (21, 32) pMEC6 has a gyrA gene with serine at position 83 but changes at positions 678 and 828, while pMEC7 encodes a wild-type gyrA gene except for tryptophan at position 83 (Fig. 5) . These plasmids were used to transform E. coli KNK453 gyrA(Ts) and DH5 gyrA96 recA. The properties of these strains are summarized in Table 2 . Strain KNK453 carries the gyrA43(Ts) allele and is viable at 37 but not at 42°C. First, we tested the quinolone resistance properties of KNK453 transformed with various plasmids at 37°C ( Table 2) . As expected, transformation with pRM386 carrying a susceptible gyrA gene did not affect the MICs of the various quinolones. However, pMEC5 conferred high-level resistance to nalidixic acid and resistance to enoxacin and ciprofloxacin, even at 37°C. The result shows that, in KNK453, quinolone-resistant gyrA genes on plasmids are dominant over the susceptible gyrA43(Ts) allele. A similar observation has been reported in E. coli KNK402, which carries the same gyrA43(Ts) allele (39) . Although the molecular basis of this dominance is not understood, it enables direct comparison of MICs for transformed cells with the parental strain. At 37 or 42°C, cells transformed with pMEC6 exhibited a wild-type susceptibility to nalidixic acid. In contrast, pMEC7 behaved like pMEC5 in requiring high levels of drug for growth inhibition. Similar results were obtained for enoxacin and ciprofloxacin (Table 2 ). These results indicate that pMEC6 carries a quinolone-susceptible gyrA gene whereas the gyrA gene in pMEC7 is quinolone resistant. As pMEC7 carries the Ser-83->Trp change in gyrA, these observations establish that this mutation alone confers high-level quinolone resistance. Moreover, based on MIC comparisons (Tables 1 and 2 ), this mutation alone accounts for the resistance observed for strain 227. We examined whether pMEC6 and pMEC7 are able to confer nalidixic acid susceptibility to the nalidixic acidresistant strain DH5, which was originally selected for growth at 100 ,ug of the drug per ml. With the exception of the gyrA43(Ts) allele, it has been found that nalidixic acidsusceptible gyrA alleles are dominant over nalidixic acidresistant ones (13) . Thus, transformation of pRM386 into DH5 rendered the strain unable to grow at 50 ,ug of nalidixic acid per ml (results not shown). Presumably, the expression of some sensitive gyrase A protein in the cell is sufficient to allow the quinolone to exert its bactericidal effect. We tested the susceptibility of DH5 transformed with various plasmid constructs to nalidixic acid at 50 ,ug/ml. Plasmid pMEC6 was found to confer drug susceptibility to DH5, whereas cells transformed with pMEC7 remained resistant (results not shown). Therefore, pMEC6 and pMEC7 must carry nalidixic acid-susceptible and -resistant gyrA alleles, respectively. These genetic studies show unequivocally that it is the Ser-83-*Trp mutation rather than changes at either 678 or 828 that renders the gyrase A protein resistant to quinolones.
Quinolone-resistant properties of the 227 gyrase A protein. Affinity-purified gyrase A protein from strain 227 comigrates on polyacrylamide gel electrophoresis with wild-type protein at an apparent molecular weight of 97,000 (Cullen et al., in press), in agreement with the actual molecular weight of 97,142 predicted from the 227 protein sequence (Fig. 3) . We have shown previously that partially purified 227 gyrase A protein, when complemented with gyrase B subunit, generates a DNA supercoiling activity about 100-fold more resistant to enoxacin than wild-type gyrase. Thus, both genetic and protein approaches demonstrate that the 227 gyrase A protein is refractory to quinolone action.
It has been suggested that quinolones may exert their bactericidal -effect through cellular processes other than changes in DNA supercoiling, e.g., by the formation of a gyrase-mediated double-stranded DNA break (4, 5 LysSerALaArgVaLVaLGLyAspVaLILeGLyLysTyrlisProHisGLyAspI.cALaVaLTyrAspThrILeVaLArgMetAlaGLn 210  230  250  270 ProPheSerLeuArgTyrMetLeuVaLAspGLyGLnGLyAsnPheGLySerl leAspGLyAspSerAtaALaALaMetArgTyrThrGLu ArgALaGLuVaLGLuVaLAspALaLysThrGLyArgGLuThrILelleVaLHisGlulLeProTyrGLnVaLAsnLysALaArgLeulle GluLeul leArgHisAtaProThrProAlaGLuAlaLysThrAlaLeuVeLAlaAsnProTrpGlnLeuGlyAsnValAlaAlaMetLeu
AAATCTGCCCGTGTCGTTGGTGACGTAATCGGTAAATACCATCCCCATGGTGACTGGGCGGTTTATGACACGATCGTCCGTATGGCGCAG -------------------------------------------------------C------C-----------T-----C---------
CCATTCTCGCTGCGTTACATGTTGGTAGACGGTCAGGGTAACTTCGGTTCCATCGACGGCGACTCTGCGGCGGCAATGCGTTATACGGAA T---C- T-
HisAsnLeuThrGLuVatl LeAsnGlyCysLeuALaTyrl leAspAspGLuAsplleSerI LeGLuGLyLeuMetGLuHisI LeProGly CACAACCTGACGGAAGTCATCAACGGTTGTCTGGCGTATATCGATGATGAAGACATCAGCATTGAAGGGCTGATGGAACACATCCCGGGG ----------------------------------------T---------

CGTGCCGAAGTAGAAGTTGACGCCAAAACCGGACGTGAAACCATTATCGTCCACGAAATTCCGTATCAGGTAAACAAAGCGCGCCTGATC --C--A-----G-T------------------T -------------------------------------------------------
GluArgAlaGtyAspAspAtaAlaArgProGLuTrpLeuGtuProGtuPheGLyVa(ArgAspG(yLeuTyrTyrLeuThrGluGlnGtn
AlaG lnA lal LeLeuAspLeuArgLeuG lnLysLeuThrGlyLeuGtuH i sGtuLysLeuLeuAspG l uTyrLysGtuLeuLeuAspG ln HisGlnGlyTyrValLysTyrGInProLeuSerGluTyrGluAlaGlnArgArgGlyGlyLysGlyLysSerAlaAtaArg IleLysGlu
GLuAspPhel leAspArgLeuLeuValAtaAsnThrHisAspHislieLeuCysPheSerSerArgGtyArgVa(TyrSerMetLysVal GAAGACTTTATCGACCGACTGCTGGTGGCGAACACTCACGACCATATTCTGTGCTTCTCCAGCCGTGGCCGCGTCTATTCGATGAAGGTC
TyrGtnLeuProGluAlaThrArgGlyALaArgGlyArgProl leValAsnLeuLeuProLeuGluGlnAspGluArgl eThrA lal le
LeuProValThrGluPheG(uGtuGtyValLysVa(PheMetAlaThrAtaAsnGlyThrValLysLysThrVatLeuThrGluPheAsn
MetLeuPheSerAlaGluGlyLysValValArgPheLysGluSerSerValArgAlaMetGlyCysAsnThrThrGlyValArgGlyl le ATGCTGTTCTCCGCTGAAGGTAAAGTGGTACGCTTTAAAGAGTCTTCTGTCCGTGCGATGGGCTGCAACACCACCGGTGTTCGTGGTATT
ArgLeuGlyGluGLyAspLysVaLValSerLeul leValProArgG(yAspGLyALalt eLeuThrAlaThrGlnAsnGlyTyrGLyLys VaLGLyArgAsnThrGlnGtyVat I leLeul teArgThrSerGluAspGluAsnVatValGlyLeuGlnArgValAlaGtuProVa LAsp GTAGGCCGTAACACCCAGGGCGTAATCCTTATCCGTACTTCGGAAGATGAAAACGTGGTGGGTCTGCAACGTGTTGCTGAACCGGTTGAC (21) proteins are shown where different.
age (6) . Wild-type gyrase induced enoxacin-dependent linearization of supercoiled pBR322 DNA (Fig. 6 , top lanes) with detectable DNA breakage at 0.5 ,ug of inhibitor per ml (lane c). Gyrase reconstituted with affinity-purified 227 gyrase A protein did not induce linearization even with 5 ,ug of enoxacin per ml (bottom wells, lane f). Mutation of the A subunit clearly affects the ability of gyrase to promote quinolone-dependent DNA cleavage.
DISCUSSION
We have cloned a gyrA gene from E. coli responsible for clinical resistance to 4-quinolone antibacterial agents. We find that a single mutation of Ser-83--Trp in the 875-amino-acid gyrase A protein is sufficient to confer high-level quinolone mutations in E. coli KL16 selected in the laboratory by one-step exposure to nalidixic acid or pipemidic acid (39) . Although these authors did not characterize the gyrase A protein, they showed that resistance can arise by mutation at several loci in the gyrA gene. They found in two instances that high-level laboratory resistance to nalidixic acid or pipemidic acid arose by mutation of Ser-83 to leucine or tryptophan, respectively. Mutation of Gln-106-lHis and Ala-67--->Ser resulted in low-level laboratory resistance to nalidixic acid and pipemidic acid, respectively. It is intriguing that clinical resistance to enoxacin during anti-infective therapy and laboratory selection for high-level pipemidic acid or nalidixic acid resistance both arise from substitution of the same residue in the gyrase A protein.
How might residue 83 participate in quinolone action? Two models may be considered that account for inhibition of gyrase by quinolones. First, the drugs could bind directly to the gyrase complex at a site adjacent to the catalytic Tyr-122 residue of the gyrase A subunit. In an alternate model, Shen and Pernet (27) have suggested, based on binding studies, that DNA and not gyrase is the target for quinolones. They envisage that there exist a few high-affinity quinolonebinding sites on DNA. Gyrase would then recognize and bind to these drug-DNA adducts. In a further elaboration of this model (cited in reference 5), Shen suggests that the quinolone binds the single-stranded DNA region formed by the transient staggered 4-bp break introduced by the gyrase A subunits. Evidence is conflicting as to whether quinolones do or do not bind to DNA (24, 27, 33) . Moreover, DNase I footprinting experiments and other data show that gyrase can bind and cleave DNA even in the absence of quinolones (6, 7) .
Whichever model applies, the clustering of quinolone resistance mutations in a highly conserved region of the gyrase A polypeptide adjacent to Tyr-122 could suggest a binding site for the quinolone. The gyrase B subunit could also participate, as Yamagishi et al. (38) have mapped and sequenced two mutations in the carboxy-terminal end of gyrase B protein that confer low-level quinolone resistance. There are conceivably two quinolone-binding sites in the symmetrical A2B2 complex involving A-B subunit interfaces, consistent with the ability of quinolones to mediate both single-and double-stranded DNA breaks (28) . It is tempting to suggest that mutations in either the gyrase A or B proteins could then interfere with quinolone binding. By reducing drug binding to the gyrase complex, the interfering effects of quinolones on DNA scission might then be obviated. We note in this regard that the tryptophan side chain introduced by mutation of Ser-83 bears some similarity in size to the ring system of a quinolone and might therefore be particularly effective in impeding drug binding.
It is not known whether these simple steric blocking ideas or more complicated models involving conformational alteration of the gyrase complex actually account for quinolone resistance. Clearly, structural and biophysical studies on quinolone-resistant gyrase complexes are necessary to resolve this issue. Quinolone-resistant gyrase A proteins have been purified from a number of clinically resistant bacterial species (1, 26; unpublished results). It remains to be determined whether mutation of Ser-83 in the E. coli gyrase A subunit (or its functional equivalent in other bacterial species) is a common feature of resistance.
